CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. AcceGen offers CD34+ progenitor cells in a phenotypically undifferentiated state. The progenitor cells are derived from cord blood of healthy donors and produced at the AcceGen facility. Progenitor cells contain two main cellular subpopulations, hematopoietic and endothelial progenitor cells. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. Samples from each donor are tested via PCR to confirm non-reactivity. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. The majority of CD133+ cells also express CD34. CD133 is a glycoprotein with sub-cellular localization in plasma membrane protrusions. In humans, this protein was originally identified as an antigenic marker expressed on hematopoietic stem cells. In addition, these cells are highly proliferative primitive hematopoietic progenitors. They can give rise to mature terminally differentiated hematopoietic cells by means of directed differentiation. AcceGen offers CD133 cells in a phenotypically undifferentiated state. The cells are derived from fresh cord blood of healthy donors and produced at the AcceGen facility. Immediately after isolation, the freshly prepared CD133 cells are cryopreserved using a serum-based cryopreservation medium. Each vial contains 100,000 cells per vial.

For research use only